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Influenza;Abstract Background: Cost-effective interventions are needed to control the
transmission of viral respiratory tract infections (RTIs) in mass gatherings. Face-
masks are a promising preventive measure, however, previous studies on the effi-
cacy of facemasks have been inconclusive. This study proposes a large-scale
182 M. Wang et al.Middle East respiratory
syndrome coronavirus;
Viral respiratory tract
infectionfacemask trial during the Hajj pilgrimage in Saudi Arabia and presents this protocol
to illustrate its feasibility and to promote both collaboration with other research
groups and additional relevant studies.
Methods/design: A cluster-randomised controlled trial is being conducted to test
the efficacy of standard facemasks in preventing symptomatic and proven viral RTIs
among pilgrims during the Hajj season in Mina, Mecca, Saudi Arabia. The trial will
compare the supervised use of facemasks versus standard measures among pil-
grims over several Hajj seasons. Cluster-randomisation will be done by accommoda-
tion tents with a 1:1 ratio. For the intervention tents, free facemasks will be
provided to be worn consistently for 7 days. Data on flu-like symptoms and mask
use will be recorded in diaries. Nasal samples will be collected from symptomatic
recruits and tested for nucleic acid of respiratory viruses. Data obtained from ques-
tionnaires, diaries and laboratory tests will be analysed to examine whether mask
use significantly reduces the frequency of laboratory-confirmed respiratory viral
infection and syndromic RTI as primary outcomes.
Conclusions: This trial will provide valuable evidence on the efficacy of standard
facemask use in preventing viral respiratory tract infections at mass gatherings.
This study is registered at the Australian New Zealand Clinical Trials Registry
(ANZCTR), ACTRN: ACTRN12613001018707 (http://www.anzctr.org.au).
ª 2014 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. All rights
reserved.1. Introduction
Viral respiratory tract infections (RTIs), including
influenza, are a major burden to public health.
During any inter-pandemic year, there are an esti-
mated 1 billion cases of influenza worldwide with
3–5 million cases of severe illness and 300,000–
500,000 deaths [1]. Fear of the global spread of
serious respiratory disease persists in the light of
past pandemics, such as the severe acute respira-
tory syndrome (SARS), the influenza A (H1N1)
pdm09 virus, and the recent emergence of the
Middle East respiratory syndrome coronavirus
(MERS-CoV) [2]. Ever-increasing international tra-
vel intensifies the risk of the spread of emerging
novel viruses, further intensifying the concern
[3]. Mass gatherings such as the Hajj pilgrimage
pose a particular risk for transmission of respira-
tory viruses [4,5].
Health authorities require cost-effective mea-
sures that prevent or limit the global transmission
of respiratory diseases. Facemasks represent a
simple and cheap supplement to the use of hand-
washing, antivirals, and vaccination in the control
of viral RTIs.
Results from previous studies examining the
effectiveness of facemasks have been either con-
flicting or inconclusive [6–17]. A randomised con-
trolled trial (RCT) in a household setting found
that adherence to facemask use decreased the risk
of influenza-like illness (ILI) [7]. Meta-analysis of
data from 6 trials shows that wearing facemasks is
protective against ILI, but did not show thatfacemasks are protective against laboratory-con-
firmed influenza, perhaps due to limitations of the
studies (Fig. 1) [18]. Interestingly, one nested
case–control study showed that intermittent face-
mask use was associated with a significantly greater
risk of infection among healthcare workers at Hajj,
suggesting perhaps that infectious material that
settles on facemasks can become a source of direct
hand transmission to the respiratory tract [19].
Standard facemasks may prevent: (i) acquisition
of infection by droplet and/or aerosol spread, or
conversely, (ii) transmission from infected subjects
[20,21].
The major limitation of previous studies is their
small sample size, and resulting lack of study
strength to detect important, albeit moderate
(e.g. 40–50%), protective effects of facemasks on
laboratory-confirmed influenza or other infections
[6,18]. The largest study undertaken to date was
a cluster-randomised trial in 509 households, with
2788 recruits; it did not find an additional benefit
from the combination of facemasks and hand
hygiene over health education (regarding preven-
tive measures) on the overall rate of laboratory-
confirmed viral infection, although there was a
benefit against secondary transmission of RTI
and laboratory-confirmed influenza. The authors
pointed to concerns about both under-powering
of the study and poor compliance with mask use
[11]. Bin Reza et al. recommended that sufficient
power may be achieved by larger trials that are
multi-centred and run for several years [6]. The
authors of this study contend, in addition, that
Fig. 1 Comparison between mask and control groups in randomised trials (adapted from Rashid et al. with the
inclusion of an additional study [9,18]).
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mask use is also critical to inducing a form of herd
immunity through widespread mask use. There are
considerable logistic and cost issues to consider in
the design and conduct of such trials, but the pub-
lic health benefits of a positive result could be
substantial.
Conducting a trial during the Hajj pilgrimage,
where approximately 2–3 million people gather
annually from all corners of the world and stay
for at least 4 days in tents in the Mina valley, offers
an excellent opportunity to conduct research in a
semi-closed setting.
This study aims to evaluate the efficacy of face-
masks in preventing laboratory-confirmed respira-
tory viral infections and syndromic RTIs.
Concurrently, the transmission pattern of influenza
at Hajj will be investigated by studying the genetic
relatedness between circulating strains using deep
genomic sequencing. In addition, the uptake of
influenza will be determined and its effectiveness
at Hajj will be evaluated using a test-negative
case–control design.
2. Methods
2.1. Primary end point
• To evaluate the efficacy of facemasks against labora-
tory-confirmed respiratory viral infections (including
influenza, MERS CoV and other respiratory viruses) at
Hajj.2.2. Secondary end points
• To investigate the transmission pattern of the influ-
enza virus at Hajj by studying the genetic relatedness
between circulating influenza viruses using deep geno-
mic sequencing.
• To determine the self-reported influenza vaccine
uptake and evaluate its effectiveness at Hajj using a
test-negative case–control design.
2.3. Study design
A large-scale cluster-randomised controlled trial
has been planned to compare the supervised use
of facemasks versus standard measures (where
some may choose to use a facemask) among pil-
grims during three consecutive Hajj pilgrimages.
Cluster-randomisation to each arm will be in a
1:1 ratio and will be done according to accommo-
dation tents. Computer-generated random num-
bers will be generated by an offsite research
coordinator who will not take part in the recruit-
ment or assessment of participants. The randomi-
sation will be stratified by gender and country of
residence to ensure a balanced and proportionate
recruitment. The key steps of the study are shown
in Fig. 2.
2.4. Recruitment
At the 2013 Hajj, over 1000 pilgrims were recruited
from Saudi Arabia, Qatar and Australia, whereas in
Table 1 Proposed number of pilgrims from each
participating country.
Countries Total number
of pilgrims
Number of
recruits
2013 2014
Saudi Arabia 1,000,000 2,200 2200
Indonesia 200,000 – 500
India 170,000 – 450
Pakistan 150,000 – 350
Turkey 120,000 – 300
Bangladesh 65,000 – 200
Morocco 32,000 – 100
Malaysia 28,000 – 100
Australia 5000 200 200
Qatar 2000 100 100
Total 1,770,000 2500 4500
2nd October
3rd October
4th October
5th October
6th October
7th October
8th October
9th October
ILI symptoms
Nasal sample from 
each subject with ILI 
Pilgrims settle into tents
Recruitment
Randomisation
Face mask No facemask wearing
Receive masks and 
demonstration.
Start wearing masks
Wear masks 
continuously
Wear masks 
continuously
Record in Hajj-health diary
Study staff collect Hajj-health diaries
Diary and nasal swabs get sent to lab in Jeddah and transported to Sydney
Data compilation and analysis
Pilgrims send the Post-Hajj diary
All pilgrims continue to record in 
Post-Hajj health diaries
All pilgrims leave Mina during the day
Record in Hajj-health diary
Nasal sample from each 
subject with ILI symptoms
Fig. 2 Key steps of the study at the Hajj 2014 (these key steps will remain the same in 2015 except that the
recruitment dates will advance by 11 days).
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at least some of the following countries: Indonesia,
Malaysia, Turkey, Morocco, India, Pakistan and
Bangladesh (Table 1).
Before the commencement of Hajj, all tour
groups will be provided with detailed information
about the study while in their own country andencouraged to participate. At Hajj, trained study
staff will approach tour group leaders in each tent
for recruitment on the first day of the pilgrims stay
in Mina. The research team members will explain
the study in detail to the assembled pilgrims and
invite them to participate in the study. If they
agree, informed consent will be obtained and a
baseline questionnaire will be completed which
will include data on demographics and clinical
information, such as recent respiratory symptoms
(Appendix A). Participants and caregivers will not
be blinded to the randomisation and will be
informed about their allocation (supervised face-
mask wearing or standard care); however, labora-
tory staff and statistical analysts will be blinded
to the allocation.
2.5. Inclusion and exclusion criteria
2.5.1. Inclusion
• Pilgrims from participating countries staying in their
respective tents.
• AgeP 18 years.
• The participant should be able to provide signed
informed consent.
A cluster-randomised controlled trial to test the efficacy of facemasks 1852.5.2. Exclusion
• Age < 18 years.
• Participation in another clinical trial investigating a
medical intervention that may interfere with the
study outcome measures, like laboratory-confirmed
viral RTI.
• Any known contraindication to mask use (e.g., allergy
to standard [surgical] mask materials).
• Refusal/or inability to sign the consent form.
2.6. Data collection
For the tents assigned to mask use, 30 facemasks
will be provided to each participant, to be worn
continuously (24/7 if possible), and replaced every
six hours (sooner if wet), for use during the 4 days
at Mina, including Arafat, and preferably for the
additional 3 days after leaving Mina.
The standard facemask for this study is 3MTM
Standard Tie-On Surgical Mask, Cat No: 1816.
Masks may be briefly removed for eating, praying,
washing, brushing teeth, or if the pilgrim experi-
ences discomfort. Oral and written information
about the instructions for correct mask wearing
and disposal will be provided to the mask group
(Appendix B). Study staff will practically demon-
strate the correct method of how to wear a mask
and also help pilgrims put on their masks for the
first time. Small plastic bags will be provided for
mask disposal and subjects will be instructed to
discard the plastic bag containing used masks into
local waste bins. A subset of used masks will be
saved for further testing by multiplex viral PCR.
A research team member will visit tents each
morning and evening to distribute additional
facemasks should pilgrims require extra, and to
document the development of any reported RTI
symptoms.
Study staff will inter alia record each tent num-
ber, the number of people recruited, and the total
number of people in each tent. Pilgrims will be pro-
vided with a Hajj Health diary (Appendix C) for the
4 days at Mina (corresponding to 2014 with 2–5
October) and a second diary, hitherto named
post-Hajj Health diary (Appendix D), for the next
3 days after leaving Mina. Each diary will have a
unique identifying barcode linked to the study par-
ticipant number. The diaries (Appendices C and D)
will contain questions on demographics, medical
conditions, and influenza vaccination history. Each
participant, whether in an intervention or a control
tent, will provide information about the presence
or absence of respiratory symptoms and fever in
the diary every day, whenever it is most convenient(morning or evening). Pilgrims will also record in
their diaries the amount of time they have worn
the mask, the number of masks used that day and
whether they were wearing one during their sleep
overnight. In addition to English, the study docu-
ments (diaries and questionnaires) will be available
in various languages, including Arabic, Bahasa Indo-
nesia and Bahasa Malaysia, and the multilingual
research team members will remain available to
help the participants who do not speak English.
Masks will not be provided to anyone in the con-
trol tents, although pilgrims may use their own sup-
ply of masks.
The Hajj Health diary (Appendix C) will be col-
lected on the evening of the fourth day. At the
same time, the post-Hajj Health diary (Appendix
D) will be distributed to these pilgrims with self-
addressed prepaid envelopes. Pilgrims will be
instructed to post these diaries to the researchers
or tour operators may collect them on behalf of
the study. Pilgrims whose Hajj Health diaries
(Appendix C) were not collected on the fourth
day will be instructed to return them together with
their post-Hajj Health diaries (Appendix D) in the
same envelope.2.7. Specimen collection and testing
In both groups, the study staff will actively search
for pilgrims suffering from RTI (defined as subjec-
tive or measured fever and at least one respiratory
symptom such as cough, sore throat and rhinor-
rhoea) twice a day. A nasopharyngeal (NP) swab
(or throat swab if an NP swab is too difficult to
obtain) will be collected from symptomatic pil-
grims by a trained staff member for later molecular
diagnostic testing to detect respiratory viruses.
The swab used will be a Copan Nylon Flocked
nasal swab in a viral transport medium.
As a part of the routine care, pilgrims in both
groups will be supplied with generic medications
(such as acetaminophen and ibuprofen) for fever
or aches.
The swabs will be stored within 2–3 h of collec-
tion at 20 C and later shipped for molecular diag-
nostic testing at the Centre for Infectious Diseases
and Microbiology Laboratory Services (CIDMLS),
Westmead Hospital, NSW, Australia. Pilgrims will
be asked to provide their email address, phone
number and mail address if they wish to receive
the result of the laboratory test. Nucleic acid test-
ing using a multiplex reverse transcriptase poly-
merase chain reaction (RT-PCR) for influenza A
and B, MERS-CoV and other coronaviruses, parain-
fluenza viruses (types 1, 2, 3 and 4), RSV A and B,
186 M. Wang et al.adenoviruses, human metapneumovirus (hMPV),
and picornaviruses will be performed on nasal
swabs.
2.8. Transmission dynamics
To determine the transmission patterns of influ-
enza viruses among Hajj pilgrims, complete
genome sequence of influenza viruses will be
obtained using a next-generation deep sequencing
protocol – using the Illumina MiSeq sequencer
available at the Westmead Hospital – which will
generate multiple reads per host (1000· coverage
per host). All sequence data generated will be
assembled and aligned using the Geneious
(http://www.geneious.com) and VICUNA packages
[22], with downstream phylogenetic (and other
evolutionary) analysis undertaken using the Gene-
ious, Seminator [23], PhyML [24] and BEAST pack-
ages [25]. With these data in hand, it will be
possible to investigate: (i) whether the study par-
ticipants were infected prior to or during the Hajj,
(ii) whether there was direct viral transmission
among the study participants (such that they har-
bour very closely related majority and minority
genetic variants), and (iii) if direct transmission is
established, whether this occurs more frequently
in the mask versus control groups.
Respiratory samples will be stored for 2 years to
revalidate any results, and then discarded accord-
ing to the standard operating procedure of CIDMLS.
2.9. Follow up
All participants will be followed up (e.g. by tele-
phone, mail, email) in their country of residence
to collect their post-Hajj Health diaries (as well
as Hajj Health diaries if not collected earlier). Con-
sent to study participation allows for the contact of
GPs/family physicians (if available) to validate any
clinical detail, including vaccination history and
subsequent infection, GP consultation, or hospital
admission.
2.10. Data analysis
Data available from questionnaires, diaries and
laboratory tests will be analysed anonymously to
examine whether mask use makes a significant dif-
ference in reducing the frequency of laboratory-
confirmed respiratory viral infection (including
influenza, coronavirus or other respiratory viruses)
or syndromic RTI. The primary endpoints (efficacy
of facemasks against RTI and laboratory-confirmed
viruses respectively) will be analysed by intention-
to-treat.The self-reported uptake rates of influenza vac-
cination will be determined and vaccine effective-
ness will be estimated based on the case-negative
case–control methodology.
The results from the genomic sequencing of the
influenza virus will assist us in understanding the
genetic relatedness of circulating influenza strains
at Hajj and the transmission pattern of influenza
among pilgrims.
2.11. Sample size calculation
Assuming a moderate intra-cluster correlation of
10% and a mean of 75 participants per cluster
(tent), and inflating the sample by a moderately
large factor of 8.4 to account for clustering, the
sample size required for a cluster-randomised con-
trolled trial to detect a reduction in laboratory-
confirmed viral respiratory infection from 12% to
6% with 80% power at 5% significance is 2976 per
arm. An additional inflation factor of 1.18 will
allow for up to a 15% loss to follow-up, loss due
to a priori infection with high penetration or
incomplete outcome data. These results in a sam-
ple size of approximately 3500 participants per
treatment making a total of 7000.
For the first primary outcome (clinical/syn-
dromic RTIs) a smaller sample would be sufficient
to answer a more generic question, namely preven-
tion of symptomatic RTI. The sample size required
for detecting a reduction from 30% prevalence of
RTIs to 15% with 80% power at 5% significance and
adjusting for clustering and loss of follow-up is
about 1170 participants per treatment making a
total of 2340 [26,27].
To achieve the full sample size, the aim will be
to conduct the study over three years. It will be
attempted to recruit a proportionate (or balanced)
number of pilgrims from each participating country
according to the number of pilgrims attending Hajj
from these countries (see Table 1).
2.12. Ethical implication
The trial has received approval from an Australian
Human Research Ethics Committee (NSW HREC
Ref: HREC/13/HNE/265), and the Joint Institu-
tional Review Board (J-IRB) of Hamad Medical Cor-
poration - Weill Cornell Medical College in Qatar
(IRB Number: 13-00039). The study coordinators
of each participating country will provide a modi-
fied Ethics Committee submission for collaborators
and assist them in applying for ethical approval
from the relevant Committees. Only participants
who provide written informed consent to take part
will be included in this study. Participants will be
A cluster-randomised controlled trial to test the efficacy of facemasks 187told that taking part in this study would be volun-
tary and confidential. All participants will be
assigned a study identification (ID) number. Data
will be collected and stored under this number
only, so that all data are stored anonymously using
study ID number. Hard copies of the questionnaires
will be stored securely in a locked filing cabinet in
locked offices and electronic data will be stored in
password-protected computer files. Only members
of the research team will have access to the data.
The hard copies will be retained for at least
15 years (or more, if the data management proto-
col of the participating country requires so) and
will be disposed according to standard data man-
agement guidelines.
3. Discussion
If conducted successfully, this study will be the
largest trial assessing the efficacy of standard face-
masks against RTIs (including influenza), and thus
would add to the evidence compendium on physical
interventions for response to an influenza pan-
demic. In addition, this will be one of the largest
studies to be conducted at Hajj involving extensive
international collaboration. Additionally, this study
will address the newly emerged MERS-CoV threat
and the potential role of facemasks in its preven-
tion. It is also hoped to involve international
collaborators in studying the burden of nasopharyn-
geal acquisition of antibiotic-resistant colonising
microbes, and assessing the impact of facemask
use on the prevention of such infections.
However, there are many challenges. An effi-
cient orchestration of the trial is needed to achieve
the study objectives; this include training a large
number of study research volunteers (n = 500),
leading the team to conduct the trial, appropriate
data collection, and storage and transport of sam-
ples in optimum temperature. Additionally, the
compliance with facemask use in intervention tents
must be optimised. Some ‘‘contamination’’ may
occur whereby subjects in control tents may use
facemasks. These issues would be addressed by
analysing data with respect to compliance of face-
mask use, in addition to intention-to-treat analysis.
Study staff will visit the intervention tents twice a
day to encourage mask use and advise people if they
have problems with wearing facemasks. Study staff
will similarly visit the control tents and encourage
the recruits to strictly maintain a record of any
facemask use, to complete their diary and to col-
lect samples from symptomatic pilgrims. A recent
pilot study showed that high compliance could be
achieved, up to 76%, where facemask usage was
recommended and the purpose explained [28].The MERS-CoV threat may impact this study in
another way. While it highlights the significance
of this trial in investigating respiratory diseases at
Hajj, the Saudi Arabian Ministry of Health has rec-
ommended that those at high risk of MERS infection
(e.g. those with chronic medical conditions, preg-
nant or aged 65+ years) postpone their pilgrimage
and that those who perform Hajj use facemasks
in crowded places and amongst coughing pilgrims
[29]. This means that the confounding behaviour
of controls will be carefully measured and included
in multiple regression analysis.
All diaries may not be returned despite the sin-
cerest of efforts. Pilgrims are required to post
the second set of diaries (post-Hajj Health diaries)
in reply-paid self-addressed envelopes, which they
might not do on time. To optimise the return of the
diaries, their study coordinators in respective
countries will send phone/mail reminders to the
recruits, and tour operators will assist in diary
collection.
Data quality may not be optimum as it relies on
self-reported symptoms. Reporting of RTI symp-
toms may be dictated by the patients interests:
patients may report more specific symptoms to
their physicians to get a prescription for antipyret-
ics/pain killers. Study staff will frequently monitor
this, but continuous monitoring will not be feasible.
In addition, the short follow-up duration of this
trial means there is a possible failure to detect
some infections. The incubation period of respira-
tory viruses may range from less than 2 days
(e.g., rhinovirus and influenza) to more than 5 days
(adenovirus, MERS-CoV) [30,31]. However, it is
believed that post-Hajj Health diaries will reduce
this shortcoming to some extent.
Despite these limitations, if successful, this pro-
ject will provide valuable data on the efficacy of
simple facemasks in preventing viral respiratory
infection in Hajj pilgrims. It is believed that this
data may be useful to other mass gatherings, such
as the Olympics, and perhaps to other closed set-
tings such as hospitals, schools, airplanes, ships
and airport settings. It also represents a powerful
opportunity to study precise patterns of virus trans-
mission through detailed comparison of circulating
viral strains. It is hoped that the outcomes of this
study will inform global health authorities about
the effective control of respiratory viral infection.Conflict of interest
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